ecancermedicalscience

Submit article

https://doi.org/10.3332/ecancer.2008.121

Abstract | Full Article |

Short Communication

Azacitidine prolongs overall survival and reduces infections and hospitalisations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update

10 Dec 2008

P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, G Sanz, AF List, SD Gore, JF Seymour, J Backstrom, L Zimmerman, D McKenzie, CL Beach, LB Silverman

Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (¡Ý20¨C30% blasts) and now meet the WHO criteria for acute myeloid leukaemia (AML) ((1999) Blood 17 3835). Considering the poor prognosis (median survival <1 year) and the poor response to chemotherapy in these pts, this sub-group analysis evaluated the effects of AZA versus conventional care regimens (CCR) on OS and on response rates in pts with WHO AML.

Article metrics: 2253 views

382

1871

1815-should-we-perform-baseline-ngs-testing-in-precursor-t-lymphoblastic-leukaemias-a-single-centre-experience-from-eastern-india

Research: Should we perform baseline NGS testing in precursor T lymphoblastic leukaemias: a single centre experience from Eastern India

Prateek Das, Sujeet Kumar, Raghwesh Ranjan, Pradeep Arumugam, Nilesh Dhole, Rohit Kumar Kori, Anil Yadav, Anil Singh, Vikramjit Kanwar, Neha Singh

6 Dec 2024

https://doi.org/10.3332/ecancer.2024.1815

Abstract | Full Article | PDF